| Literature DB >> 20202929 |
Peter R Berti1, Alison Mildon, Kendra Siekmans, Barbara Main, Carolyn Macdonald.
Abstract
BACKGROUND: Evaluations of large-scale health and nutrition programmes in developing countries are needed for determining the effectiveness of interventions. This article critically analyses a non-governmental organization (NGO)-led large-scale, multi-country, 10-year micronutrient and health (MICAH) programme with an 'adequacy evaluation', that is, a documentation of time trends in the expected direction.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20202929 PMCID: PMC2846447 DOI: 10.1093/ije/dyp389
Source DB: PubMed Journal: Int J Epidemiol ISSN: 0300-5771 Impact factor: 7.196
Summary table of MICAH interventions
| Approximate number of ‘direct’ beneficiaries | 1.8 million | 150 000 | 1.8 million | 255 420 | ||
| Total implementation cost, US$ million | 16.6 | 3.3 | 14.5 | 3.2 | ||
| Total cost of evaluation, US$ | 559 345 | 147 866 | 1 293 018 | 172 243 | ||
| Total cost, US$ million | 17.0 | 3.5 | 15.5 | 3.3 | ||
| US$ per direct beneficiary per year (Phase I/Phase II) | 1.39/0.83 | 3.37/2.14 | 1.06/5.06 | 1.85/1.28 | ||
| Increase intake and bioavailability of micronutrients (iron, iodine and vitamin A) | Vitamin A supplementation | Pre-school children | D, T, M | P, D, T, A, M | D, T, M | |
| School-age children | D, T, A, M | |||||
| Post-partum women | D, T, M | P, D, T, A, M | D, T, M | |||
| Iron supplementation | Pre-school children | P, D, T, A, M | P, D, T, A, M | P, D, T, M | ||
| School-age children | P, D, T, A, M | |||||
| Women of childbearing age | P, D, T, A, M | P, D, T, A, M | ||||
| Pregnant women | P, T, M | P, D, T, A, M | P, D, T, A, M | P, D, T, M | ||
| Fortification | Iodized salt promotion | P, D, T, A, M | P, D, T, A, M | T, A, M | T, A, M | |
| Small-scale flour fortification | P, D, T, A, M | P, D, T, A, M | ||||
| Dietary diversification | Small animal rearing | P, D, T, A, M | P, D, T, M | P, D, T, A, M | P, D, T, M | |
| Vegetable gardens | P,D,T,A,M | P, D, T, M | P, D, T, A, M | P, D, T, M | ||
| Fruit tree cultivation | P, D, T, A, M | P, D, T, M | P, D, T, A, M | P, D, T, M | ||
| Infant and young child feeding | Promotion of optimal breastfeeding and complementary feeding | T, A, M | T, A, M | T, A, M | T, A, M | |
| Reduce prevalence of diseases that affect micronutrient status (diarrhoeal, parasitic and vaccine-preventable) | Water and sanitation | Provision of clean water | P, D, T, M | P, D, T, M | P, D, T, M | P, D, T, M |
| Latrine construction | P, D, T, M | P, D, T, M | P, D, T, M | P, D, T, M | ||
| Garbage disposal construction | T, M | T, M | T, M | T, M | ||
| Malaria control | ITN distribution | P, D, T, M | P, D, T, M | P, D, T, M | P, D, T, M | |
| Chemoprophylaxis to pregnant women | P, D, M | M | P, D, T, M | P, D, T, M | ||
| Malaria treatment to pre-school children | P, D, M | T | P, D, T, M | P, D, T, M | ||
| Treatment of worms and parasites | Deworming of pre-school children | P, D, T, M | P, D, T, M | P, D, T, A, M | P, D, T, M | |
| Deworming of school-age children | P, D, T, M | P, D, T, M | P, D, T, A, M | P, D, T, M | ||
| Schistosomiasis treatment | P, D, T, M | P, D, T, M | P, D, T, A, M | P, D, T, M | ||
| Immunization | Support EPI campaigns | P, D, T, M | P, D, T, M | P, D, T, M | D, T, M | |
| Diarrhoea treatment | Promotion of ORT | T | T | P, D, T | T | |
| HIV/AIDS prevention | IEC re: HIV and AIDS | T | T | T | T | |
| Build local capacity for delivery systems to improve micronutrient status | Education | Health and nutrition IEC to communities | T, M | D, T, M | D, T, M | D, T, M |
| Staff and partner training | T | T | T | T | ||
| Advocacy | Influence national policies on nutrition issues | A | A | A | A | |
| Use of media to communicate nutrition and health messages | T, A | T, A | T, A | T, A | ||
P: procurement; D: delivery/distribution (includes both transport to distribution sites such as health centres and direct delivery to beneficiaries); T: training (includes both community education and training of implementing staff/volunteers); A: advocacy; M: monitoring; ITN: insecticide-treated bednet; EPI: expanded programme on immunization; ORT: oral rehydration therapy; IEC: Information, Education and Communication.
aBlank cells indicate that MICAH did not work on that target group/activity in that country.
bBased on target population in MICAH programme communities; not including the significant number of indirect beneficiaries (e.g. 4.7 million in Malawi) of MICAH’s national advocacy and intervention efforts (e.g. iodized salt coverage, EPI and vitamin A supplementation (VAS) campaigns).
cCosts are in US$ and based on exchange rates applicable at the time of purchase. World Vision Canada technical support and programme management costs, as well as overhead costs at country and Canada levels, are included.
Programme coverage rates and outcome indicator prevalences at baseline (1996 or 1997), follow-up (2000) and endline (2004), and comparable available DHS data
When coverage rates and outcome indicators are discordant (changes not in expected directions) cells are shaded grey.
When the effectiveness is similar to or higher than previously observed efficacy, the text is shown in bold.
All DHS data were from http://www.statcompiler.com/ accessed on 9 October 2009.
Methods used for quality control assessment
| • Comparison of magnitude of SDs of continuous variables to SDs in other, well-controlled studies | • SDs of MICAH will be similar to othersb |
| • Consistency of relationships between coverage and outcomes; congruency in chain of results | • Increased VAC coverage, iodized salt use and iron supplementation coverage will lead to decreased nightblindness and higher breast-milk retinol, higher urinary iodine, and, possibly, reduced anaemia, respectively |
| • Comparison of magnitude of apparent MICAH effect to observed effects in efficacy trials | • Magnitude of MICAH effects will not greatly exceed maximum magnitude of effects in efficacy trials |
| • Pattern of cross-sectional growth curves | • Average HAZ and WAZ of infants <3 months of age will be near 0; |
| • Change in average Z-scores by month of age will not fluctuate widely | |
| • Sample size at each age (by month) will be approximately equal | |
| • Pattern of immunization coverage | • BCG > DPT3 ∼ OPV3 ≥ measles |
aThese methods were developed post hoc. The acceptable levels (e.g. what constituted ‘similar’ or ‘widely’) were decided after the analyses were done. Limits of this method are described in the ‘Discussion’ section.
bThis method of comparing SDs with reference populations has been recommended for anthropometrics. We assume that common levels of variations will exist for other variables.
BCG, Bacille Calmette-Guérin Vaccine; DPT3, 3 doses of Diptheria, Pertussis, Tetanus Vaccine; OPV3, 3 doses of Oral Polio Vaccine.
The maximum efficacy found in the literature for clinical, biochemical and biological indicators tracked in MICAH
| Controlled trials | Large-scale programmes | |
|---|---|---|
| Vitamin A | ||
| Night blindness in children <5 years of age | From 1.2 to 0.1% | From 2.3 to 0.6% |
| Bitot’s spots in children <5 years of age | From 0.8 to 0.5% | From 1.1 to 0.5% |
| Low breast-milk retinol | From 70 to 36%, | |
| Iodine | ||
| Total goitre rate | Although it is not uncommon to have no change in goitre prevalence, | |
| Low urinary iodine | From ∼25 to 0% | From 39, 56, 77 and 1.5% to ∼0% |
| Iron | ||
| Anaemia in women 15–49 years of age | From 7 to 1.6%; | From 73.3 to 25.4% |
| Anaemia in pregnant women | As high as from 70 to 10%; | From 62 to 52%, |
| Anaemia in children <5 years of age | As high as from 72 to 19%; | From 85 to 68%; |
| Malaria | ||
| Malaria in pregnant women | ITNs have protective efficacy of 0.2657 for malaria parasitemia | |
| Malaria in children <5 years of age | Average of protective efficacy of 0.13, maximum of 0.57 with stable malaria and 0.42 with unstable malaria; | |
| Anthropometrics | ||
| HAZ < –2 | Average increase in Z-score was ∼0.3, but single studies as high as 1.75. | |
| WAZ < –2 | Average increase in Z-score ∼0.3(60, 61). Increase of 0.3 Z-score would lead to reduction in underweight of ∼10–15%. | |
| Exclusive breastfeeding (EBF) | ||
| EBF for 6 months | 0.6–7.9%; | As high as 46–68%31 |
RR, Relative Risk.
SDs of continuous variables in MICAH surveys in baseline (1996 or 1997), follow-up (2000) and endline (2004) compared with examples from the literature, for quality control purposes
| 1997 | 2000 | 2004 | 1997 | 2000 | 2004 | 1996 | 2000 | 2004 | 1997 | 2000 | 2004 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Breast-milk retinol (µmol/l) | 1.4 | 0.5 | 0.70, 0.4835 1.19, 0.9936 | ||||||||||
| Urinary iodine—school-age children (µg/l) | 25.4 | 140.0 | 132.1 | 76.9 | 98.0 | 20.5 | 38.9 | 145, 80, | |||||
| Haemoglobin— women (g/dl) | 1.8 | 1.1 | 1.6 | 1.9 | 1.9 | 1.4 | 1.7 | 1.6 | 2.1 | 1.9 | 2.0 | 1.941 | |
| Haemoglobin— pregnant women (g/dl) | 1.7 | 1.5 | 1.6 | 1.5 | 1.7 | 1.6 | 1.5 | 1.6 | 1.7 | 1.5,421.8, | |||
| Haemoglobin— children <5 years of age (g/dl) | 1.8 | 1.5 | 1.8 | 1.8 | 1.7 | 1.8 | 1.9 | 1.6 | 1.941 | ||||
| HAZ | 1.5 | 1.4 | 1.3 | 1.2 | 1.2 | 1.5 | 1.5 | 1.2 | 1.5 | 1.5 | 1.3 | 1.8423 | |
| WAZ | 1.3 | 1.1 | 1.3 | 1.2 | 1.2 | 1.4 | 1.5 | 1.1 | 1.4 | 1.4 | 1.3 | 1.50 | |
Unexpected or unusual values are indicated in bold.
Summary of impact of MICAH, by indicator and country
| Vitamin A | ||||
| Night blindness in children <5 years of age | Lowa | |||
| Bitot’s spots in children <5 years of age | Highb | |||
| Night blindness in school-age children | ||||
| Bitot’s spots in school-age children | ||||
| Low breast-milk retinol | Not assessedd | |||
| Iodine | ||||
| Total goitre rate | Nonea | Highc | ||
| Low urinary iodine | Lowa | Not assessedd | ||
| Iron | ||||
| Anaemia in women 15–49 years of age | ||||
| Anaemia in pregnant women | ||||
| Anaemia in children <5 years of age | ||||
| Malaria | ||||
| Malaria in women | Higha | |||
| Malaria in pregnant women | ||||
| Malaria in children <5 years of age | ||||
| HAZ < –2 | Noneb | |||
| WAZ < –2 |
High, moderate, low, none and negative indicate magnitude of change in indicators. High: similar to upper end of impact of controlled trials; moderate: less than trials and of a range common in other programmes; low: small effect, but greater than zero. t-tests conducted for continuous variables and chi-square tests for categorical variables. Results with P < 0.05 indicated with bold text. Quality of data: ahigh quality; bmoderate quality; clow quality; dtoo poor quality to assess impact.
Difference in differences of coverage rates, EBF and prevalence of stunting, wasting and underweight between MICAH surveys and DHS surveys
| VAC coverage, children <5 years of age | 16 | |||
| VAC coverage, post-partum women | 10 | |||
| Measles coverage | 44 | –5 | 13 | 7 |
| Access to protected water source | 41 | 20 | –2 | –4 |
| Access to latrines | –10 | 2.5 | 2 | –7 |
| EBF for 6 months | 9 | 14 | ||
| Stunting (HAZ <–2) | –4 | 0 | 3 | 9 |
| Underweight (WAZ <–2) | –6 | 8 | 10 | 11 |
aCalculated in general as (EndlineMICAH–BaselineMICAH) – (EndlineDHS – BaselineDHS) for those variables where ‘higher’ is ‘better’. For stunting and underweight, where ‘lower’ is better, calculated as: (EndlineDHS – BaselineDHS) – (EndlineMICAH–BaselineMICAH). A positive value indicates that MICAH villages improved more than the rural, nationally-representative, samples. DHS data used when available within 1 year of timing of MICAH survey; DHS data not available in baseline years for Ethiopia and Malawi, therefore mid-line year (2000) used as ‘baseline’ in calculation.
b(2004MICAH-2000MICAH) – (2005DHS – 2000DHS).
c(2004MICAH-1997MICAH) – (2003DHS – 1998DHS).
d(2004MICAH-2000MICAH) – (2004DHS – 2000DHS).
e(2004MICAH-1997MICAH) – (2004DHS – 1996DHS).